229 related articles for article (PubMed ID: 22568867)
1. Nestin expression identifies ependymoma patients with poor outcome.
Milde T; Hielscher T; Witt H; Kool M; Mack SC; Deubzer HE; Oehme I; Lodrini M; Benner A; Taylor MD; von Deimling A; Kulozik AE; Pfister SM; Witt O; Korshunov A
Brain Pathol; 2012 Nov; 22(6):848-60. PubMed ID: 22568867
[TBL] [Abstract][Full Text] [Related]
2. Study of stem cell marker nestin and its correlation with vascular endothelial growth factor and microvascular density in ependymomas.
Nambirajan A; Sharma MC; Gupta RK; Suri V; Singh M; Sarkar C
Neuropathol Appl Neurobiol; 2014 Oct; 40(6):714-25. PubMed ID: 24224478
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
4. Prognostic marker analysis in pediatric intracranial ependymomas.
McLendon RE; Lipp E; Satterfield D; Ehinger M; Austin A; Fleming D; Perkinson K; Lefaivre M; Zagzag D; Wiener B; Gururangan S; Fuchs H; Friedman HS; Herndon JE; Healy P
J Neurooncol; 2015 Apr; 122(2):255-61. PubMed ID: 25563815
[TBL] [Abstract][Full Text] [Related]
5. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases.
Korshunov A; Golanov A; Timirgaz V
J Neurol Sci; 2000 Aug; 177(1):72-82. PubMed ID: 10967185
[TBL] [Abstract][Full Text] [Related]
7. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
8. Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.
Chen C; Chen L; Yao Y; Qin Z; Chen H
J Neurooncol; 2016 Mar; 127(1):43-52. PubMed ID: 26615563
[TBL] [Abstract][Full Text] [Related]
9. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas.
Suzuki S; Oka H; Kawano N; Tanaka S; Utsuki S; Fujii K
Brain Tumor Pathol; 2001; 18(2):151-4. PubMed ID: 11908872
[TBL] [Abstract][Full Text] [Related]
11. Predictors of outcome in an AIEOP series of childhood ependymomas: a multifactorial analysis.
Modena P; Buttarelli FR; Miceli R; Piccinin E; Baldi C; Antonelli M; Morra I; Lauriola L; Di Rocco C; Garrè ML; Sardi I; Genitori L; Maestro R; Gandola L; Facchinetti F; Collini P; Sozzi G; Giangaspero F; Massimino M
Neuro Oncol; 2012 Nov; 14(11):1346-56. PubMed ID: 23076205
[TBL] [Abstract][Full Text] [Related]
12. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas.
Cage TA; Clark AJ; Aranda D; Gupta N; Sun PP; Parsa AT; Auguste KI
J Neurosurg Pediatr; 2013 Jun; 11(6):673-81. PubMed ID: 23540528
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review.
Zawrocki A; Iżycka-Świeszewska E; Papierz W; Liberski PP; Zakrzewski K; Biernat W
Folia Neuropathol; 2011; 49(2):94-102. PubMed ID: 21845537
[TBL] [Abstract][Full Text] [Related]
15. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival.
Strojnik T; Røsland GV; Sakariassen PO; Kavalar R; Lah T
Surg Neurol; 2007 Aug; 68(2):133-43; discussion 143-4. PubMed ID: 17537489
[TBL] [Abstract][Full Text] [Related]
16. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of localization and grading in intracranial ependymomas of childhood.
Ernestus RI; Schröder R; Stützer H; Klug N
Childs Nerv Syst; 1996 Sep; 12(9):522-6. PubMed ID: 8906366
[TBL] [Abstract][Full Text] [Related]
18. Pathology of spinal ependymomas: an institutional experience over 25 years in 134 patients.
Tarapore PE; Modera P; Naujokas A; Oh MC; Amin B; Tihan T; Parsa AT; Ames CP; Chou D; Mummaneni PV; Weinstein PR
Neurosurgery; 2013 Aug; 73(2):247-55; discussion 255. PubMed ID: 23670032
[TBL] [Abstract][Full Text] [Related]
19. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.
Korshunov A; Sycheva R; Timirgaz V; Golanov A
J Neurooncol; 1999; 45(3):219-27. PubMed ID: 10845392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
